January 8, 2011 -- The J.P. Morgan Healthcare Conference will include a China track for the first time, with fourteen China-based life science companies presenting their business plans; Shanxi Zhendong Pharma completed its IPO on the ChiNext Exchange, raising $211 million; Merck KGaA of Germany acquired Beijing Skywing Technology for $18.2 million; Golden Meditech will float a secondary listing on the Taiwan Stock Exchange; Sihuan Pharma will invest $208 million into new facilities in Tonghua City, Jilin Province; United Labs received SFDA approval for three additional insulin products; Chiva Pharma in-licensed China rights for two clinical-stage liver drugs from Ligand Pharma; and Mingyuan Medicare Development will begin a clinical validation study of its C12A protein microarray, a tumor marker kit. More details…..
